Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Knox

Showing results (771-780 of 829) with videos related to

Pageof 83
Sort By:
Bioorganic & Medicinal Chemistry Letters|September 28, 2013
Discovery of (S,E)-3-(2-fluorophenyl)-N-(1-(3-(pyridin-3-yloxy)phenyl)ethyl)-acrylamide as a potent and efficacious KCNQ2 (Kv7.2) opener for the treatment of neuropathic painYong-Jin Wu, Charles M Conway, Li-Qiang Sun, et al.
Heliyon|July 8, 2024
Inspiring a convergent engineering approach to measure and model the tissue microenvironmentRishyashring R Iyer, Catherine C Applegate, Opeyemi H Arogundade, et al.
JHEP Reports : Innovation in Hepatology|January 26, 2026
Pembrolizumab and stereotactic body radiotherapy combined in advanced hepatocellular carcinoma post sorafenib - A phase II trial (PEMRAD)Grainne M O'Kane, Aruz Mesci, Raymond W Jang, et al.
Cancer Research Communications|February 16, 2024
CALGB 80802 (Alliance): Impact of Sorafenib with and without Doxorubicin on Hepatitis C Infection in Patients with Advanced Hepatocellular CarcinomaGhassan K Abou-Alfa, Susan M Geyer, Andrew B Nixon, et al.
Journal of Viral Hepatitis|February 12, 2016
A phase 3b study of sofosbuvir plus ribavirin in treatment-naive and treatment-experienced Korean patients chronically infected with genotype 2 hepatitis C virusS H Ahn, Y S Lim, K S Lee, et al.
JAMA Oncology|December 19, 2024
Stereotactic Body Radiotherapy vs Sorafenib Alone in Hepatocellular Carcinoma: The NRG Oncology/RTOG 1112 Phase 3 Randomized Clinical TrialLaura A Dawson, Kathryn A Winter, Jennifer J Knox, et al.
Immunity|May 1, 2020
The Transcription Factor T-bet Resolves Memory B Cell Subsets with Distinct Tissue Distributions and Antibody Specificities in Mice and HumansJohn L Johnson, Rebecca L Rosenthal, James J Knox, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 14, 2022
Pembrolizumab Monotherapy for Previously Untreated Advanced Hepatocellular Carcinoma: Data from the Open-Label, Phase II KEYNOTE-224 TrialGontran Verset, Ivan Borbath, Mark Karwal, et al.
Journal of Medicinal Chemistry|July 11, 2003
(S)-N-[1-(3-morpholin-4-ylphenyl)ethyl]- 3-phenylacrylamide: an orally bioavailable KCNQ2 opener with significant activity in a cortical spreading depression model of migraineYong-Jin Wu, Christopher G Boissard, Corinne Greco, et al.
Journal of Hepatology|February 20, 2025
A phase III randomized study of first-line NUC-1031/cisplatin vs. gemcitabine/cisplatin in advanced biliary tract cancerJennifer J Knox, Mairéad G McNamara, Igor S Bazin, et al.
Pageof 83

Showing results (771-780 of 829) with videos related to

Sort By:
Pageof 83
Bioorganic & Medicinal Chemistry Letters|September 28, 2013
Discovery of (S,E)-3-(2-fluorophenyl)-N-(1-(3-(pyridin-3-yloxy)phenyl)ethyl)-acrylamide as a potent and efficacious KCNQ2 (Kv7.2) opener for the treatment of neuropathic painYong-Jin Wu, Charles M Conway, Li-Qiang Sun, et al.
Heliyon|July 8, 2024
Inspiring a convergent engineering approach to measure and model the tissue microenvironmentRishyashring R Iyer, Catherine C Applegate, Opeyemi H Arogundade, et al.
JHEP Reports : Innovation in Hepatology|January 26, 2026
Pembrolizumab and stereotactic body radiotherapy combined in advanced hepatocellular carcinoma post sorafenib - A phase II trial (PEMRAD)Grainne M O'Kane, Aruz Mesci, Raymond W Jang, et al.
Cancer Research Communications|February 16, 2024
CALGB 80802 (Alliance): Impact of Sorafenib with and without Doxorubicin on Hepatitis C Infection in Patients with Advanced Hepatocellular CarcinomaGhassan K Abou-Alfa, Susan M Geyer, Andrew B Nixon, et al.
Journal of Viral Hepatitis|February 12, 2016
A phase 3b study of sofosbuvir plus ribavirin in treatment-naive and treatment-experienced Korean patients chronically infected with genotype 2 hepatitis C virusS H Ahn, Y S Lim, K S Lee, et al.
JAMA Oncology|December 19, 2024
Stereotactic Body Radiotherapy vs Sorafenib Alone in Hepatocellular Carcinoma: The NRG Oncology/RTOG 1112 Phase 3 Randomized Clinical TrialLaura A Dawson, Kathryn A Winter, Jennifer J Knox, et al.
Immunity|May 1, 2020
The Transcription Factor T-bet Resolves Memory B Cell Subsets with Distinct Tissue Distributions and Antibody Specificities in Mice and HumansJohn L Johnson, Rebecca L Rosenthal, James J Knox, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 14, 2022
Pembrolizumab Monotherapy for Previously Untreated Advanced Hepatocellular Carcinoma: Data from the Open-Label, Phase II KEYNOTE-224 TrialGontran Verset, Ivan Borbath, Mark Karwal, et al.
Journal of Medicinal Chemistry|July 11, 2003
(S)-N-[1-(3-morpholin-4-ylphenyl)ethyl]- 3-phenylacrylamide: an orally bioavailable KCNQ2 opener with significant activity in a cortical spreading depression model of migraineYong-Jin Wu, Christopher G Boissard, Corinne Greco, et al.
Journal of Hepatology|February 20, 2025
A phase III randomized study of first-line NUC-1031/cisplatin vs. gemcitabine/cisplatin in advanced biliary tract cancerJennifer J Knox, Mairéad G McNamara, Igor S Bazin, et al.
Pageof 83